EP3499230A4 - Verfahren zur unterstützung der diagnose von morbus alzheimer mittels urinbiomarker - Google Patents

Verfahren zur unterstützung der diagnose von morbus alzheimer mittels urinbiomarker Download PDF

Info

Publication number
EP3499230A4
EP3499230A4 EP17839323.7A EP17839323A EP3499230A4 EP 3499230 A4 EP3499230 A4 EP 3499230A4 EP 17839323 A EP17839323 A EP 17839323A EP 3499230 A4 EP3499230 A4 EP 3499230A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
assisting diagnosis
urine biomarker
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17839323.7A
Other languages
English (en)
French (fr)
Other versions
EP3499230A1 (de
Inventor
Kiyonori Katsuragi
Kiyotaka Machida
Hirokazu KARIYAZONO
Ryo HIGASHIYAMA
Hironori Kobayashi
Yoko Saijo
Ayumi Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of EP3499230A1 publication Critical patent/EP3499230A1/de
Publication of EP3499230A4 publication Critical patent/EP3499230A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/825—Metallothioneins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP17839323.7A 2016-08-09 2017-08-03 Verfahren zur unterstützung der diagnose von morbus alzheimer mittels urinbiomarker Withdrawn EP3499230A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016156820 2016-08-09
PCT/JP2017/028173 WO2018030252A1 (ja) 2016-08-09 2017-08-03 尿バイオマーカーを用いたアルツハイマー病の診断補助方法

Publications (2)

Publication Number Publication Date
EP3499230A1 EP3499230A1 (de) 2019-06-19
EP3499230A4 true EP3499230A4 (de) 2020-07-29

Family

ID=61162590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17839323.7A Withdrawn EP3499230A4 (de) 2016-08-09 2017-08-03 Verfahren zur unterstützung der diagnose von morbus alzheimer mittels urinbiomarker

Country Status (6)

Country Link
US (1) US20190257842A1 (de)
EP (1) EP3499230A4 (de)
JP (1) JPWO2018030252A1 (de)
CN (1) CN109791139A (de)
TW (1) TW201805627A (de)
WO (1) WO2018030252A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021071219A1 (ko) * 2019-10-07 2021-04-15 조한나 퇴행성 신경질환의 진단용 바이오마커
CN113125746B (zh) * 2021-03-05 2022-05-24 华中科技大学 用于预测老年人发生ad的风险的生物标志物和试剂盒及其应用
ES2924776A1 (es) * 2021-03-25 2022-10-10 Univ Castilla La Mancha Metodos para el diagnostico y pronostico de la enfermedad de alzheimer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220013A1 (en) * 2005-07-14 2008-09-11 Denis Hochstrasser Diagnostic Method for Brain Damage-Related Disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694816B1 (de) * 2003-11-07 2013-08-28 Ciphergen Biosystems, Inc. Biomarker für morbus alzheimer
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
AP2008004634A0 (en) * 2006-03-23 2008-10-31 Emelta De Guzman Breyer Apolipoprotein fingerprinting technique
WO2008106076A2 (en) * 2007-02-27 2008-09-04 Merck & Co., Inc. Methods for monitoring disease progression of alzheimer's disease using csf markers from longitudinal samples
JP6392202B2 (ja) * 2012-03-13 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティ 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質
WO2014207888A1 (ja) * 2013-06-28 2014-12-31 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカー及び当該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2015060317A1 (ja) * 2013-10-22 2015-04-30 長谷川亨 神経変性疾患の検査方法
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
JP6532650B2 (ja) * 2014-03-10 2019-06-19 浜松ホトニクス株式会社 癌の検査方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080220013A1 (en) * 2005-07-14 2008-09-11 Denis Hochstrasser Diagnostic Method for Brain Damage-Related Disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAO WANG ET AL: "Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer's disease in patients with the apolipoprotein E [epsilon]4 genotype", BIOMARKERS, vol. 20, no. 1, 2 January 2015 (2015-01-02), GB, pages 84 - 88, XP055668567, ISSN: 1354-750X, DOI: 10.3109/1354750X.2014.994036 *
GHANBARI H ET AL: "BIOCHEMICAL ASSAY FOR AD7C-NTP IN URINE AS AN ALZHEIMER'S DISEASE MARKER", JOURNAL OF CLINICAL LABORATORY ANALYSIS, NEW YORK, NY, US, vol. 12, no. 5, 1 January 1998 (1998-01-01), pages 285 - 288, XP009002172, ISSN: 0887-8013, DOI: 10.1002/(SICI)1098-2825(1998)12:5<285::AID-JCLA6>3.0.CO;2-5 *
KOSTNER K M ET AL: "URINARY APOLIPOPROTEIN (A) EXCRETION IN PATIENTS WITH PROTEINURIA", ANNALS OF MEDICINE, TAYLOR & FRANCIS A B, SE, vol. 30, no. 5, 1 October 1998 (1998-10-01), pages 497 - 502, XP009076675, ISSN: 0785-3890 *
M. DEGERMAN GUNNARSSON ET AL: "Pittsburgh Compound-B and Alzheimer's Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study", DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, vol. 29, no. 3, 1 January 2010 (2010-01-01), CH, pages 204 - 212, XP055668576, ISSN: 1420-8008, DOI: 10.1159/000281832 *
See also references of WO2018030252A1 *

Also Published As

Publication number Publication date
TW201805627A (zh) 2018-02-16
EP3499230A1 (de) 2019-06-19
CN109791139A (zh) 2019-05-21
WO2018030252A1 (ja) 2018-02-15
JPWO2018030252A1 (ja) 2019-06-20
US20190257842A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer&#39;s disease
EP3898971A4 (de) Verfahren zum nachweis einer krankheit durch analyse von rna
EP3555629A4 (de) Verwendung von apoe4-motif-vermittelten genen zur diagnose und behandlung von morbus alzheimer
EP3216392A4 (de) Hirnerkrankungsdiagnoseassistenzsystem, hirnerkrankungsdiagnoseassistenzverfahren und programm
IL247123A0 (en) Methods and systems for diagnosing or predicting the progression of Parkinson&#39;s disease using body-fixed sensors
EP3060913A4 (de) Biomarker und diagnoseverfahren für morbus alzheimer und andere neurodegenerative erkrankungen
HK1214671A1 (zh) 輔助疾病診療的分析系統、裝置及方法
EP3847281A4 (de) Verfahren und maschinelles lernen zur krankheitsdiagnose
EP3577455A4 (de) Biomarker zur diagnose und charakterisierung von morbus alzheimer
EP3299473A4 (de) Verfahren zur diagnose einer frühen form von morbus alzheimer oder leichter kognitiver beeinträchtigung
EP3471625A4 (de) Medizinische anatomiequantifizierung: computergestütztes diagnosewerkzeug
EP3374964A4 (de) Differenzialdiagnose von periapikalen erkrankungen auf der grundlage von ergebnissen einer bildanalyse
EP3269823A4 (de) Verfahren zur unterstützung der erkennung von morbus alzheimer oder leichter kognitiver beeinträchtigung
EP3633372A4 (de) Biomarker für morbus alzheimer
EP3472201A4 (de) Verfahren zur differentiellen diagnose von autoimmunerkrankungen
EP3567118A4 (de) Verfahren zur diagnose von herzkrankheiten durch bakterielle metagenomanalyse
EP3433614A4 (de) Verwendung von klinischen parametern zur vorhersage von sirs
EP3546943A4 (de) Zusammensetzung zur diagnose von krankheiten
EP3285071A4 (de) Biomarkerzusammensetzungen zur diagnose von morbus still, diagnosekit und diagnoseverfahren
GB201804724D0 (en) Method of diagnosing cceliac disease
IL266778A (en) Combined discrimination for the differential diagnosis of Alzheimer&#39;s disease
EP3499230A4 (de) Verfahren zur unterstützung der diagnose von morbus alzheimer mittels urinbiomarker
EP3537155A4 (de) Verfahren zur bestimmung des risikos von morbus alzheimer
EP3345000A4 (de) Neuartige blutzellenbiomarker für spät einsetzendem morbus alzheimer
EP3653128A4 (de) Bildgebungsverfahren zum erhalten eines menschlichen skeletts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20190306

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101ALI20200218BHEP

Ipc: G01N 33/68 20060101ALI20200218BHEP

Ipc: G01N 33/493 20060101AFI20200218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20200625

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101ALI20200619BHEP

Ipc: G01N 33/68 20060101ALI20200619BHEP

Ipc: G01N 33/493 20060101AFI20200619BHEP

18W Application withdrawn

Effective date: 20200714